Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Prepaid Assets came in at $514910.0 in Q1 2026, up 881.25% year-on-year from $52475.0 in Q1 2025, and down 48.61% on a QoQ basis from $1.0 million in Q4 2025.
Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Prepaid Assets data on file, last reported at $514910.0 in Q1 2026.
- On a quarterly basis, Prepaid Assets rose 881.25% year-over-year to $514910.0 in Q1 2026; TTM through Mar 2026 was $514910.0, a 881.25% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 21.24% from the prior year.
- Prepaid Assets for Q1 2026 stood at $514910.0, down from $1.0 million in the prior quarter.
- Over the last five years, Prepaid Assets for IKT reached as high as $1.2 million in Q1 2022 and fell as low as $52475.0 in Q1 2025.
- Historically, Prepaid Assets has averaged $627276.5 across 5 years, with a median of $682628.0 in 2025.
- Across the five-year window, Prepaid Assets soared 944.5% in 2022 and plunged 77.52% in 2024, its largest moves.
- Year by year, Prepaid Assets stood at $1.1 million in 2022, then sank by 33.86% to $739179.0 in 2023, then increased by 11.81% to $826473.0 in 2024, then increased by 21.24% to $1.0 million in 2025, then slumped by 48.61% to $514910.0 in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $514910.0 in Q1 2026, $1.0 million in Q4 2025, and $210566.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 514,910.00 |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 210,566.00 |
| Jun 30, 2025 | 682,628.00 |
| Mar 31, 2025 | 52,475.00 |
| Dec 31, 2024 | 826,473.00 |
| Sep 30, 2024 | 280,914.00 |
| Jun 30, 2024 | 306,300.00 |
| Mar 31, 2024 | 207,422.00 |
| Dec 31, 2023 | 739,179.00 |
| Sep 30, 2023 | 347,565.00 |
| Jun 30, 2023 | 543,923.00 |
| Mar 31, 2023 | 922,764.00 |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 932,419.00 |
| Jun 30, 2022 | 811,482.00 |
| Mar 31, 2022 | 1.17 Mn |
| Dec 31, 2021 | 107,000.00 |
| Sep 30, 2021 | 264,381.00 |
| Jun 30, 2021 | 958,779.00 |